Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Key Publications

Friedrich M &  Pohin M & Jackson MA et al. IL-1-driven stromal-neutrophil interaction in deep ulcers identifies a pathotype of therapy non-responsive inflammatory bowel disease patients. Nature Medicine 2021; 27: 1970.  

Friedrich M & Travis S. Shining a Light on Barrier Function. Gastroenterology 2023; 164(2):184.

Friedrich M & Pohin M & Powrie F. Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. Immunity 2019; 50:992. 

West N & Hegazy A. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nature Medicine 2017; 23:579.

Korsunsky I & Wei K & Pohin M & Kim EY & Barone F. Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases. Med 2022; 3(7): 481.

Hackstein CP et al. A conserved population of MHC II-restricted, innate-like, commensal-reactive T cells in the gut of humans and mice. Nature Communications 2022; 13(1):7472.

Tillack C & Ehmann LM & Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63:567.

Friedrich M et al. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunology 2015; 8:943.

Demetriou P et al. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals. Nature Immunology 2020; 21:1232.

Matthias Friedrich

Dr. rer. biol. hum.

Group Leader (Wellcome Trust Career Development Award)

Gastrointestinal Pathophysiology - Translational Research and Experimental Medicine


Our team is interested in the cellular and molecular mechanisms of chronic inflammation and fibrosis. Whilst the focus is on Inflammatory Bowel Diseases (IBDs), we aim to identify shared and distinct patho-mechanisms across organs. Combining cutting edge digital pathology and AI approaches, spatial/single-cell/bulk genomics and proteomics, highly multiplexed immunohistochemistry and flow cytometry, we profile large patient cohorts. This is complemented by mechanistic studies of in vivo disease models and in vitro organotypic tissue cultures. Current projects strive to personalise medical therapy in IBD, finding alternative treatments for fibrotic Crohn's disease, and establishing a molecular basis for symptoms in ulcerative colitis.   


Research Assistants:

Osheen Sharma

Laboratory and Administrative Assistants:

Kate Hutton


Hosuk Ryou 

Kristina Clark (Academic Clinical Lecturer, co-supervised)

DPhil students:

Zhi Wong (co-supervised)

Rahul Ravindran (co-supervised)

Julia Pakpoor (co-supervised)

Tom Hosack (co-supervised)

Clinical Fellows:

Khalid Shamiyah


Kaiyang Song